SHINE Isotope Project Courts Investors at Wisconsin BIO Convention
In support of a second round of start-up capital, representatives from SHINE Medical Technologies took their case to the Wisconsin business community at the state’s International BIO convention. Within the next four years, the company—which is backed heavily by U.S. federal dollars and the Morgridge Institute—claims that it could be producing enough imaging isotopes at its nuclear reactor to meet half the medical needs of the country. “This is a potential $600 million a year market,’’ SHINE CEO Greg Piefer said, according to the website Wisbusiness. Domestic isotope security in the United States has been a matter of concern in recent years, as a handful of reactors provide the world’s supply of molybdenum-99-derived isotopes. Canadian researchers are advocating for a fusion-based solution via a distributed network of particle accelerators.